PETRINI, IACOPO
 Distribuzione geografica
Continente #
NA - Nord America 598
EU - Europa 301
AS - Asia 50
AF - Africa 6
SA - Sud America 5
OC - Oceania 3
Totale 963
Nazione #
US - Stati Uniti d'America 589
IT - Italia 132
FR - Francia 113
DE - Germania 20
VN - Vietnam 14
IN - India 10
UA - Ucraina 9
CN - Cina 8
SG - Singapore 8
CA - Canada 5
GB - Regno Unito 5
ZA - Sudafrica 5
HN - Honduras 4
AU - Australia 3
CL - Cile 3
FI - Finlandia 3
NL - Olanda 3
RS - Serbia 3
BR - Brasile 2
CZ - Repubblica Ceca 2
HK - Hong Kong 2
IL - Israele 2
MK - Macedonia 2
RU - Federazione Russa 2
TH - Thailandia 2
AE - Emirati Arabi Uniti 1
AT - Austria 1
BD - Bangladesh 1
EG - Egitto 1
GR - Grecia 1
HR - Croazia 1
HU - Ungheria 1
ID - Indonesia 1
LU - Lussemburgo 1
LV - Lettonia 1
SE - Svezia 1
TR - Turchia 1
Totale 963
Città #
Fairfield 57
Santa Cruz 48
Ashburn 44
Seattle 44
Buffalo 34
Woodbridge 33
Columbus 29
Houston 29
Serra 27
Wilmington 22
Pisa 18
Cambridge 14
Chicago 14
Paris 13
Dong Ket 10
Florence 10
Las Vegas 10
Phoenix 9
Redmond 9
Ann Arbor 8
Des Moines 8
Rome 8
Milan 6
Riva 5
Turin 5
Beijing 4
Bengaluru 4
Clearwater 4
Henderson 4
Los Angeles 4
San Diego 4
Dallas 3
London 3
Newark 3
San Francisco 3
Shanghai 3
University Park 3
Belgrade 2
Brisbane 2
Capannori 2
Centro 2
Frankfurt Am Main 2
Helsinki 2
Johannesburg 2
Lucca 2
Mount Prospect 2
Mountain View 2
Muizenberg 2
Ottawa 2
Provo 2
Tappahannock 2
Vedano Olona 2
Vicopisano 2
Westfield 2
Amsterdam 1
Atlanta 1
Auburn 1
Bari 1
Barishal 1
Bhubaneswar 1
Bissen 1
Blacksburg 1
Bremen 1
Brierley Hill 1
Büdelsdorf 1
Cairo 1
Carrara 1
Cassano d'Adda 1
Chennai 1
Cosenza 1
Crugers 1
Delhi 1
Dubai 1
Dulles 1
Edison 1
Fleming Island 1
Fort Wayne 1
Fort Worth 1
Forte dei Marmi 1
Gyor 1
Herndon 1
Hyderabad 1
Islington 1
Istanbul 1
Kowloon 1
Lake Forest 1
Lappeenranta 1
Lehavim 1
Levico Terme 1
Livorno 1
Lombard 1
Lugo 1
Melbourne 1
Miami 1
Milford 1
Milpitas 1
Montecatini Terme 1
New York 1
Nice 1
Nuremberg 1
Totale 636
Nome #
Contribution of KRAS mutations and c.2369C > T (p.T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNA, file e0d6c929-f65c-fcf8-e053-d805fe0aa794 123
Myelodysplastic syndromes: advantages of a combined cytogenetic and molecular diagnostic workup, file e0d6c92c-7650-fcf8-e053-d805fe0aa794 119
Nanotopography Induced Human Bone Marrow Mesangiogenic Progenitor Cells (MPCs) to Mesenchymal Stromal Cells (MSCs) Transition, file e0d6c928-8a94-fcf8-e053-d805fe0aa794 105
ED-B fibronectin expression is a marker of epithelial-mesenchymal transition in translational oncology, file e0d6c92a-ddff-fcf8-e053-d805fe0aa794 102
Patients with NSCLC may display a low ratio of p.T790M vs. activating EGFR mutations in plasma at disease progression: implications for personalised treatment, file e0d6c92a-0b5b-fcf8-e053-d805fe0aa794 101
Implications of KRAS mutations in acquired resistance to treatment in NSCLC, file e0d6c929-b8bf-fcf8-e053-d805fe0aa794 81
KRAS has a role in acquired resistance to EGFR-TKIs in NSCLC: an analysis on circulating tumor DNA, file e0d6c927-4b88-fcf8-e053-d805fe0aa794 73
Defining TCRγδ lymphoproliferative disorders by combined immunophenotypic and molecular evaluation, file 491c47e5-9e0b-4d01-bd94-f2ab61d4d8ea 54
Hypertermic Intrathoracic Chemotherapy (HITHOC) for thymoma: a narrative review on indications and results, file e0d6c931-65e4-fcf8-e053-d805fe0aa794 52
The Droplet Digital PCR: A New Valid Molecular Approach for the Assessment of B-RAF V600E Mutation in Hairy Cell Leukemia, file e0d6c92c-8d1b-fcf8-e053-d805fe0aa794 44
A multiparametric approach to improve the prediction of response to immunotherapy in patients with metastatic NSCLC, file e0d6c92f-d61a-fcf8-e053-d805fe0aa794 17
Integrating Liquid Biopsy and Radiomics to Monitor Clonal Heterogeneity of EGFR-Positive Non-Small Cell Lung Cancer, file e0d6c931-86aa-fcf8-e053-d805fe0aa794 14
Best practices for the management of thymic epithelial tumors: A position paper by the Italian collaborative group for ThYmic MalignanciEs (TYME), file e0d6c931-352f-fcf8-e053-d805fe0aa794 12
The amount of activating EGFR mutations in circulating cell-free DNA is a marker to monitor osimertinib response, file e0d6c92b-0ec5-fcf8-e053-d805fe0aa794 6
null, file 5e5f81c9-122d-49b8-a7f3-4f644dedd4e9 5
Growth Factor Content in Human Sera Affects the Isolation of Mesangiogenic Progenitor Cells (MPCs) from Human Bone Marrow, file e0d6c930-fd7a-fcf8-e053-d805fe0aa794 5
Clinical utility of Next Generation Sequencing of plasma cell-free DNA for the molecular profiling of patients with NSCLC at diagnosis and disease progression, file 3e032f53-6ae6-4971-82e4-f37c31e92552 4
Real-Time PCR and Droplet Digital PCR: two techniques for detection of the JAK2(V617F) mutation in Philadelphia-negative chronic myeloproliferative neoplasms, file e0d6c92b-6a5f-fcf8-e053-d805fe0aa794 4
The increase in activating EGFR mutation in plasma is an early biomarker to monitor response to osimertinib: a case report, file e0d6c92d-2e09-fcf8-e053-d805fe0aa794 4
ErbB in NSCLC as a molecular target: Current evidences and future directions, file e0d6c92f-3a19-fcf8-e053-d805fe0aa794 4
The mitochondrial citrate carrier, SLC25A1, drives stemness and therapy resistance in non-small cell lung cancer, file 48d49005-15f6-4f17-8d46-eb46aea29512 3
Thymectomy in myasthenic patients with thymoma: killing two birds with one stone, file 9401f7ea-0eb9-4f0c-82ff-123fffae9d58 3
Surgical treatment of pleural recurrence of thymoma: Is hyperthermic intrathoracic chemotherapy worthwhile?, file adbf56cd-90e3-4b78-a22d-5d820c0223d6 3
Molecular analysis of cell-free circulating DNA for the diagnosis of somatic mutations associated with resistance to tyrosine kinase inhibitors in non-small-cell lung cancer., file e0d6c92a-000b-fcf8-e053-d805fe0aa794 3
From the beginning to resistance: study of plasma monitoring and resistance mechanisms in a cohort of patients treated with osimertinib for advanced T790M-positive NSCLC, file e0d6c92d-1d69-fcf8-e053-d805fe0aa794 3
Clinical management of patients with thymic epithelial tumors: the recommendations endorsed by the Italian Association of Medical Oncology (AIOM), file e0d6c931-73d6-fcf8-e053-d805fe0aa794 3
Multiple Resistance Mechanisms to Tyrosine Kinase Inhibitors in EGFR Mutated Lung Adenocarcinoma: A Case Report Harboring EGFR Mutations, MET Amplification, and Squamous Cell Transformation, file e0d6c931-88d5-fcf8-e053-d805fe0aa794 3
Stereotactic body radiation therapy for the treatment of pleural metastases in patients with thymoma: A retrospective review of 22 patients, file e0d6c931-d803-fcf8-e053-d805fe0aa794 3
Mesenchymal Stem Cell in Pancreatic Islet Transplantation, file 0570c191-12e9-477f-be67-345624561ecd 2
Detecting cell-of-origin and cancer-specific methylation features of cell-free DNA from Nanopore sequencing, file 118c888f-c51f-41bd-b165-6ce71f80f5ec 2
Gene-network analysis predicts clinical response to immunotherapy in patients affected by NSCLC, file 48b77d6e-b69e-421f-8bd1-c6e5df672123 2
Somatic mutations of thymic epithelial tumors with myasthenia gravis, file 7a67000c-f644-4b95-876c-a4d3c04c393c 2
Editorial: Primary and acquired resistance in lung cancer, file a0f5ef2c-d7aa-4723-b4eb-b122aae2eebe 2
ED-B-Containing Isoform of Fibronectin in Tumor Microenvironment of Thymomas: A Target for a Theragnostic Approach, file c6051580-2f8b-4076-b6ca-dbd2c2a4bb76 2
EGFR and AKT1 overexpression are mutually exclusive and associated with a poor survival in resected gastric adenocarcinomas, file c8f454f7-c928-478a-a8b4-18486d59862e 2
PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC, file ca08e4d8-1580-410b-8ec6-e63d72cb6bbf 2
Isolation and characterization of two newly established thymoma PDXs from two relapses of the same patient: a new tool to investigate thymic malignancies, file d4f561b8-5a53-455c-ad43-35a5f889510f 2
Medical treatment of malignant pleural mesothelioma relapses, file e097b3a7-b9bb-41ce-a2ec-0aa7bb9da6d1 2
Recent advances in epigenomics in NSCLC: Real-time detection and therapeutic implications, file e0d6c928-24f7-fcf8-e053-d805fe0aa794 2
Detection of ALK and KRAS Mutations in Circulating Tumor DNA of Patients With Advanced ALK-Positive NSCLC With Disease Progression During Crizotinib Treatment, file e0d6c929-e088-fcf8-e053-d805fe0aa794 2
EGFR-TKIs in non-small-cell lung cancer: Focus on clinical pharmacology and mechanisms of resistance, file e0d6c92a-ac58-fcf8-e053-d805fe0aa794 2
Understanding the Mechanisms of Resistance in EGFR-Positive NSCLC: From Tissue to Liquid Biopsy to Guide Treatment Strategy, file e0d6c92d-8bde-fcf8-e053-d805fe0aa794 2
Incidence of T790M in Patients With NSCLC Progressed to Gefitinib, Erlotinib, and Afatinib: A Study on Circulating Cell-free DNA, file e0d6c92e-2b61-fcf8-e053-d805fe0aa794 2
RELEVENT Trial: Phase II Trial of Ramucirumab, Carboplatin, and Paclitaxel in Previously Untreated Thymic Carcinoma/B3 Thymoma With Area of Carcinoma, file e0d6c931-2848-fcf8-e053-d805fe0aa794 2
Phase II Trial of Maintenance Treatment With IL2 and Zoledronate in Multiple Myeloma After Bone Marrow Transplantation: Biological and Clinical Results, file e0d6c931-5deb-fcf8-e053-d805fe0aa794 2
Human adult mesangiogenic progenitor cells reveal an early angiogenic potential, which is lost after mesengenic differentiation, file f4802f2a-a4f5-4759-9abe-c7c890d08ff3 2
Increased production of inflammatory cytokines by circulating monocytes in mesial temporal lobe epilepsy: A possible role in drug resistance, file 0980e62b-ad63-4c4e-9407-37d1afc558ef 1
Clinical evidence and adverse event management update of patients with RET- rearranged advanced non-small-cell lung cancer (NSCLC) treated with pralsetinib, file 6c1900a9-2680-4042-a372-afd76435d557 1
Pulmonary cancers across different histotypes share hybrid tuft cell/ionocyte-like molecular features and potentially druggable vulnerabilities, file 906e29db-9d05-4668-8923-c20565c5fd9c 1
Amivantamab in the Treatment of Metastatic NSCLC: Patient Selection and Special Considerations, file d2cd7718-4bc9-4535-8b65-41a82c9ade8b 1
GTF2I mutations are common in thymic epithelial tumors but not in hematological malignancies, file e0d6c92c-7657-fcf8-e053-d805fe0aa794 1
EXTENSIVE ANALYSIS OF T CELL RECEPTOR GAMMA (TCRG) GENE REARRANGEMENTS REVEALS A SIMILAR REPERTOIRE IN EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA) AND IN HYPEREOSINOPHILIC SYNDROME (HES), file e0d6c92c-8ef9-fcf8-e053-d805fe0aa794 1
Circulating tumor DNA and the future of EGFR-mutant lung cancer treatment, file e0d6c92e-64ee-fcf8-e053-d805fe0aa794 1
Biomarkers and gene signatures to predict durable response to pembrolizumab in non‐small cell lung cancer, file e0d6c931-abd2-fcf8-e053-d805fe0aa794 1
Treatment-driven tumour heterogeneity and drug resistance: Lessons from solid tumours, file e0d6c931-b0e1-fcf8-e053-d805fe0aa794 1
Nanopore sequencing from liquid biopsy: analysis of copy number variations from cell-free DNA of lung cancer patients, file ea069cb0-08f4-4079-ac73-ecc3cd7eb6a5 1
Third-Line Chemotherapy with Irinotecan plus 5-Fluorouracil in Caucasian Metastatic Gastric Cancer Patients, file ef13900c-a3ee-4e40-8daf-030104d49539 1
Totale 1.000
Categoria #
all - tutte 3.620
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3.620


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201910 0 0 0 0 0 0 0 0 0 0 0 10
2019/2020184 3 7 4 7 29 21 19 31 25 10 14 14
2020/2021116 7 10 13 6 10 5 8 12 9 9 11 16
2021/2022164 12 5 5 10 18 8 10 5 13 3 55 20
2022/2023185 3 6 50 26 17 18 8 10 5 16 21 5
2023/2024293 9 13 18 11 22 39 7 37 5 24 95 13
Totale 1.000